Sarah Matousek, MD
Pulmonary Disease · Enid, OKNPI 1083874267
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.0%), education and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Intuitive Surgical at 41.3% of the total. 2025 is the largest year on record at $10,052, 2.8 times the $3,557 reported in 2019. Among pulmonary disease clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 679 payments — averaging $31.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- Grifols USA, LLC$3K
- GSK$2K
- AstraZeneca$2K
- Insmed, Inc.$1K
- Boehringer Ingelheim$747
- plus $4K from 22 others
What the payments were for
- Speaking & faculty fees$1,5007%
- Travel & lodging$2681%
- Food & beverage$10,62750%
- Education$8,84742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $8,768 |
| Grifols USA, LLC | 60 | $2,611 |
| GSK | 165 | $2,037 |
| AstraZeneca | 71 | $1,656 |
| Insmed, Inc. | 82 | $1,414 |
| Boehringer Ingelheim | 51 | $747 |
| Actelion Pharmaceuticals US, Inc. | 35 | $656 |
| Regeneron Healthcare Solutions, Inc. | 26 | $563 |
| Sunovion Pharmaceuticals Inc. | 51 | $507 |
| Novartis | 19 | $407 |
| Genentech USA, Inc. | 25 | $352 |
| Mylan Specialty L.p. | 20 | $315 |
| Sanofi | 9 | $216 |
| Pfizer | 13 | $177 |
| Fisher & Paykel Healthcare Inc | 2 | $114 |
| Electromed, Inc. | 9 | $88 |
| Amgen | 5 | $81 |
| ANI Pharmaceuticals, Inc. | 4 | $80 |
| Baxter Healthcare | 4 | $78 |
| Viatris Specialty LLC | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $62 |
| United Therapeutics Corporation | 4 | $61 |
| Circassia Inc. | 4 | $55 |
| Monaghan Medical Corporation | 1 | $39 |
| Merck | 3 | $36 |
| Philips North America LLC | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,762
- Prolastin-C$1,125
- Prolastin-C Liquid$375
- BREZTRI$357
- FASENRA$357
- BEVESPI AEROSPHERE$252
- TEZSPIRE$105
- AIRSUPRA$105
How this compares
$21,242 in reported general payments places this provider in the 90th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 887 | $636,030 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 66 | $348,779 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 377 | $263,180 |
| Breo ElliptaFluticasone/Vilanterol | 217 | $114,504 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 181 | $91,033 |
| Spiriva RespimatTiotropium Bromide | 125 | $88,698 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 99 | $55,636 |
| Dupixent PenDupilumab | 15 | $49,934 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 61 | $36,887 |
| Advair HfaFluticasone Propion/Salmeterol | 46 | $22,793 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $19,131 |
| Incruse ElliptaUmeclidinium Bromide | 47 | $16,112 |
| Arnuity ElliptaFluticasone Furoate | 49 | $14,818 |
| Ventolin HfaAlbuterol Sulfate | 154 | $13,695 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 30 | $12,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,037 | $872,4971,381 claims |
| Grifols USA, LLCProlastin C | $2,611 | $348,77966 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,656 | $295,015464 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $747 | $181,221285 claims |
| MerckDulera | $36 | $11,85726 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $18 | $2,75314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Enid
- Michael HullEdmond$642K
- John KingreyOklahoma City$332K
- Jennifer BierachTulsa$141K
- Hassan AbouhouliTulsa$103K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Grace KennedyTulsa$57K
- Nancy NagleOkc$51K
- Dennis ParkerOkc$46K
- Walter BoomerTulsa$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.